FDA Downclassifies Multiplex Nucleic Acid Assays
This article was originally published in The Gray Sheet
Executive Summary
FDA has decided to relax its classification of multiplex nucleic acid assays to detect microorganisms and resistance markers in the blood but with special controls to mitigate concerns with potential to misinterpret test results.
You may also be interested in...
Guidance On Nucleic Acid-Based IVDs Recommends Analytical, Clinical Studies
An FDA final guidance released Aug. 27 on highly multiplexed microbiological in vitro nucleic-acid based diagnostics recommends studies on both the analytical and clinical performance of the devices.
New Products In Brief
New assays and devices on the market include Roche’s cytomegalovirus viral load test, Nanosphere’s infectious disease assay.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.